Exploring the Relationship between Antioxidant Enzymes, Oxidative Stress Markers, and Clinical Profile in Relapsing-Remitting Multiple Sclerosis

被引:13
|
作者
Bizon, Anna [1 ]
Chojdak-Lukasiewicz, Justyna [2 ]
Budrewicz, Slawomir [2 ]
Pokryszko-Dragan, Anna [2 ]
Piwowar, Agnieszka [1 ]
机构
[1] Wroclaw Med Univ, Fac Pharm, Dept Toxicol, Borowska 211, PL-50556 Wroclaw, Poland
[2] Wroclaw Med Univ, Fac Med, Dept Neurol, Borowska 213, PL-50556 Wroclaw, Poland
关键词
relapsing-remitting multiple sclerosis; oxidative stress; antioxidants; GLUTATHIONE-PEROXIDASE; SUPEROXIDE-DISMUTASE; CATALASE; SELENIUM; ERYTHROCYTES; SERUM;
D O I
10.3390/antiox12081638
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
We aimed to investigate the extent of alterations in the pro/antioxidant balance in the blood of patients with relapsing-remitting multiple sclerosis (RRMS) in relation to drug-modified therapy, gender, disability score, and disease duration. 161 patients (67 men and 94 women, aged 24-69 years, median 43.0) and 29 healthy individuals (9 men and 20 women, aged 25-68 years, median 41.0) were included in the study. We measured the activity of superoxide dismutase (SOD), glutathione peroxidase (GPx), and catalase (CAT) as well as the concentration of interleukin-6 (IL-6), lipid peroxidation parameters (LPO), total oxidant status (TOS), and total antioxidant capacity (TAS). The activity of SOD did not show any significant differences between patients with RRMS and the control group in our study. In contrast, significant decreased GPx activity and increased CAT activity was observed in the blood of patients with RRMS compared to the control group. Additionally, the activity of CAT was influenced by gender and the use of disease-modifying therapies. Disease-modifying therapies also affected the concentration of TOS, TAS, and LPO. Our studies indicated that enhancing GPx activity may be more beneficial to providing potential therapeutic strategies aimed at modulating antioxidant defenses to mitigate oxidative stress in this disease.
引用
收藏
页数:17
相关论文
共 50 条
  • [21] Effect of natalizumab on oxidative damage biomarkers in relapsing-remitting multiple sclerosis
    Inmaculada Tasset
    Carmen Bahamonde
    Eduardo Agüera
    Cristina Conde
    Antonio H. Cruz
    Aleyda Pérez-Herrera
    Félix Gascón
    Ana I. Giraldo
    María C. Ruiz
    Rafael Lillo
    Fernando Sánchez-López
    Isaac Túnez
    Pharmacological Reports, 2013, 65 : 624 - 631
  • [22] Disability Progression in a Clinical Trial of Relapsing-Remitting Multiple Sclerosis
    Rudick, Richard A.
    Lee, Jar-Chi
    Cutter, Gary R.
    Miller, Deborah M.
    Bourdette, Dennis
    Weinstock-Guttman, Bianca
    Hyde, Robert
    Zhang, Hao
    You, Xiaojun
    ARCHIVES OF NEUROLOGY, 2010, 67 (11) : 1329 - 1335
  • [23] Clinical and demographic characteristics of relapsing-remitting multiple sclerosis in Kazakhstan
    Kozhakanova, S.
    Almakhanova, K.
    Zhusupova, A.
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 750 - 751
  • [24] THE RELATIONSHIP BETWEEN INSOMNIA SYMPTOM SEVERITY AND FATIGUE IN PERSONS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS
    Culnan, E.
    Kaye, J.
    Macintosh, M.
    Morse, C.
    Germain, A.
    Schultheis, M.
    Spiers, M.
    Kloss, J. D.
    SLEEP, 2017, 40 : A384 - A384
  • [25] The relationship between incidental learning and executive functions in relapsing-remitting multiple sclerosis patients
    Galiani, Agostina
    Pagania Cassara, Fatima
    Sinay, Vladimiro
    Roca, Maria
    Bruno, Diana
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 (01) : 150 - 151
  • [26] Effect of natalizumab on oxidative damage biomarkers in relapsing-remitting multiple sclerosis
    Tasset, Inmaculada
    Bahamonde, Carmen
    Agueera, Eduardo
    Conde, Cristina
    Cruz, Antonio H.
    Perez-Herrera, Aleyda
    Gascon, Felix
    Giraldo, Ana I.
    Ruiz, Maria C.
    Lillo, Rafael
    Sanchez-Lopez, Fernando
    Tunez, Isaac
    PHARMACOLOGICAL REPORTS, 2013, 65 (03) : 624 - 631
  • [27] Elevated melatonin levels in natalizumab-treated female patients with relapsing-remitting multiple sclerosis: Relationship to oxidative stress
    Bahamonde, Carmen
    Conde, Cristina
    Agueera, Eduardo
    Lillo, Rafael
    Luque, Evelio
    Gascon, Felix
    Feijoo, Montserrat
    Cruz, Antonio H.
    Sanchez-Lopez, Fernando
    Tunez, Isaac
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2014, 730 : 26 - 30
  • [28] Clinical experience with cladribine in patients with relapsing-remitting multiple sclerosis
    Hodgkinson, S.
    Lizak, N.
    Butler, E.
    Lechner-Scott, J.
    Slee, M.
    McCombe, P.
    Shaw, C.
    Skibina, O.
    Vucic, S.
    Shuey, N.
    Barnett, M.
    Parratt, J.
    Butzkueven, H.
    Jack, D.
    Fabris, J.
    Kalincik, T.
    Jokubaitis, V. G.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (09) : NP64 - NP65
  • [29] Neurotrophic factors and clinical recovery in relapsing-remitting multiple sclerosis
    Caggiula, M
    Batocchi, AR
    Frisullo, G
    Angelucci, F
    Patanella, AK
    Sancricca, C
    Nociti, V
    Tonali, PA
    Mirabella, M
    JOURNAL OF NEUROLOGY, 2004, 251 : 118 - 118
  • [30] Clinical features of relapsing-remitting multiple sclerosis prognostic factors
    Fernández-Fernández, O
    REVISTA DE NEUROLOGIA, 2002, 35 (11) : 1067 - 1073